Development of local generic version of Pfizer Vax; China seeks license; Report
Beijing: It is reported that China is preparing to sign an agreement with the American multinational pharmaceutical company Pfizer Inc.
China and Pfizer are in talks for a license to manufacture a regional generic version of Pfizer’s Paxlovid vaccine amid the spread of a new variant of Covid in China, Archyde.com reported, citing various sources.
Once the license is obtained, domestic pharmaceutical companies in China will be able to manufacture and distribute the generic version of Paxlovid vaccine in China.
According to the report, discussions with Pfizer are being conducted under the leadership of the National Medical Products Administration (NMPA), China’s medical products regulator. The talks started last month.
China aims to reach a final decision on the terms of the agreement before the new lunar year, which begins on January 22, the report said.
Meanwhile, since the ‘Zero Covid Policy’ was abandoned last month, China’s hospitals are facing a major crisis due to overcrowding of Covid patients.
China approved paxlovid vaccine in February last year.
Content Highlight: Report says China is in talks with Pfizer for generic COVID drug